Shunzhen Zheng
Overview
Explore the profile of Shunzhen Zheng including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
74
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
An W, Zhang K, Li G, Zheng S, Cao Y, Liu J
Transl Oncol
. 2024 Dec;
52():102234.
PMID: 39674093
Cholangiocarcinoma remains a challenging primary hepatobiliary malignancy with dismal prognosis. Photodynamic therapy (PDT),a less invasive treatment, has been found to inhibit the proliferation and induce ferroptosis, apoptosis and necrosis in...
2.
Zheng S, Chan S, Liu F, Liu J, Chow P, Toh H, et al.
Cancers (Basel)
. 2024 Apr;
16(8).
PMID: 38672664
Hepatocellular carcinoma (HCC) is the most common form of liver cancer, accounting for ~90% of liver neoplasms. It is the second leading cause of cancer-related deaths and the seventh most...
3.
Liu Y, Zheng S, Wang T, Fang Z, Kong J, Liu J
Front Cell Dev Biol
. 2022 Mar;
10:842220.
PMID: 35252205
Hepatocellular carcinoma (HCC) is the most common primary liver cancer with a poor prognosis. 5-methylcytosine (m5C) modification plays a nonnegligible role in tumor pathogenesis and progression. However, little is known...
4.
Guo S, Liu J, Zheng S
Clin Gastroenterol Hepatol
. 2021 Jul;
20(5):e915-e916.
PMID: 34332117
No abstract available.
5.
He J, Li G, Liu X, Ma L, Zhang J, Zheng S, et al.
Onco Targets Ther
. 2020 Sep;
13:9169-9184.
PMID: 32982305
Purpose: Intrahepatic cholangiocarcinoma (ICC) is an aggressive malignant tumor characterized by high malignancy and poor prognosis. Although the efficacy of sorafenib against cholangiocarcinoma cell lines has been demonstrated in vivo...
6.
Liu F, Zhu C, Gao P, Zheng S, Li C
Anticancer Drugs
. 2020 Aug;
31(8):836-846.
PMID: 32796405
Ubiquitin-conjugating enzyme E2T (UBE2T) is overexpressed in several human cancer cells, but a role in cholangiocarcinoma (CAA) progression has not been investigated. We analyzed the expression of UBE2T in CAA...
7.
He J, Li G, Liu X, Ma L, Zhang P, Zhang J, et al.
Biomed Res Int
. 2020 May;
2020:1936385.
PMID: 32382531
Hepatocellular carcinoma (HCC) is one of the most common malignant tumors, and its prognosis is still poor. Mesencephalic astrocyte-derived neurotrophic factor (MANF) plays a key role in endoplasmic reticulum stress....
8.
Zheng S, Sun P, Liu X, Li G, Gong W, Liu J
Medicine (Baltimore)
. 2018 Dec;
97(50):e13703.
PMID: 30558084
Many patients in China have portal hypertension secondary to liver cirrhosis. Splenectomy and devascularization have become an efficacious surgical procedure for portal hypertension, and has been recommended in China as...
9.
Yuan X, Cheng G, Yu J, Zheng S, Sun C, Sun Q, et al.
Oncotarget
. 2017 Apr;
8(14):23120-23129.
PMID: 28416747
Telomerase activation via induction of the catalytic component telomerase reverse transcriptase (TERT) plays essential roles in malignant transformation. TERT promoter-activating mutations were recently identified as a novel mechanism to activate...
10.
Zheng S, Chang S, Lu J, Chen Z, Xie L, Nie Y, et al.
PLoS One
. 2011 Jun;
6(6):e21064.
PMID: 21695227
Background: Hepatocellular carcinoma (HCC) is the third most common cause of cancer related mortality worldwide. 9-Nitrocamptothecin (9NC) is a potent topoisomerase-I inhibitor with strong anticancer effect. To increase the solubility...